VistaGen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average – What’s Next?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.64 and traded as low as $0.5503. VistaGen Therapeutics shares last traded at $0.5574, with a volume of 315,608 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a research report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Trading Up 1.2%

The company has a market cap of $22.08 million, a price-to-earnings ratio of -0.29 and a beta of 0.32. The company has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $2.69.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.14 million. Sell-side analysts anticipate that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in VistaGen Therapeutics during the fourth quarter valued at approximately $25,000. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics during the 1st quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics in the 3rd quarter valued at $39,000. Tudor Investment Corp ET AL bought a new stake in VistaGen Therapeutics in the fourth quarter valued at $50,000. Finally, Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.